LINC01752: A Potential Drug Target and Biomarker (G101929395)

Target Name: LINC01752

NCBI ID: G101929395

LINC01752

Other Name(s): Long intergenic non-protein coding RNA 1752 | long intergenic non-protein coding RNA 1752

LINC01752: A Potential Drug Target and Biomarker

Non-protein-coding RNAs (NP-C RNAs) have emerged as a promising source of new biomarkers and drug targets in recent years. These small non-coding RNAs play a crucial role in regulating gene expression and have been implicated in a wide range of biological processes, including development, growth, and metabolism. One of the most promising NP-C RNAs is LINC01752, which has been identified as a potential drug target and biomarker.

LINC01752 is a long intergenic non-protein-coding RNA (lncRNA) that is located between the intron and exon of the gene ZNF21. ZNF21 is a key regulator of neuronal development and function, and is implicated in a wide range of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. LINC01752 is a non-coding RNA that has been shown to be highly expressed in the brains of individuals with these disorders.

The structure and function of LINC01752 have been studied extensively using a variety of techniques, including RNA sequencing, RNA-based assays, and in vitro transcription assays. These studies have provided a wealth of information about the biology of LINC01752 and its potential role in disease.

One of the most exciting aspects of LINC01752 is its potential as a drug target. The use of small molecules to modulate gene expression is a common approach in drug development, and LINC01752 is an attractive target for this approach because of its well-characterized function and its involvement in several key biological processes.

Several studies have shown that LINC01752 is involved in the regulation of neuronal excitability and synaptic plasticity. LINC01752 has been shown to play a role in the regulation of neurotransmitter release and in the modulation of synaptic strength, which are critical for the function of neurons.

In addition to its role in neuronal function, LINC01752 has also been shown to be involved in the regulation of immune responses and inflammation. These processes are critical for maintaining the health and function of the brain and body, and LINC01752 may be a useful target for the development of new treatments for a wide range of inflammatory and neurodegenerative disorders.

The potential utility of LINC01752 as a drug target is further underscored by its expression in the brains of individuals with neurological and psychiatric disorders. The fact that LINC01752 is expressed in the brains of individuals with Alzheimer's disease, Parkinson's disease, and other disorders suggests that it may be an effective target for the development of new treatments for these disorders.

In addition to its potential as a drug target, LINC01752 is also a promising biomarker for a wide range of neurological and psychiatric disorders. The fact that LINC01752 is expressed in the brains of individuals with these disorders suggests that it may be a useful biomarker for the diagnosis and treatment of these disorders.

The identification of LINC01752 as a potential drug target and biomarker has significant implications for the development of new treatments for a wide range of neurological and psychiatric disorders. Further research is needed to fully understand the role of LINC01752 in these disorders and to develop effective treatments based on this understanding.

In conclusion, LINC01752 is a long intergenic non-protein-coding RNA that has been shown to be involved in the regulation of gene expression and the modulation of several key biological processes, including neuronal function, immune responses, and inflammation. Its expression in the brains of individuals with neurological and psychiatric disorders suggests that it may be a promising target for the development of new treatments for these disorders. Further research is needed to fully understand the role of LINC01752 in these disorders and to develop effective treatments based on this understanding.

Protein Name: Long Intergenic Non-protein Coding RNA 1752

The "LINC01752 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01752 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets